Welcome to our dedicated page for AGILE THERAPEUTICS news (Ticker: AGRX), a resource for investors and traders seeking the latest updates and insights on AGILE THERAPEUTICS stock.
Agile Therapeutics, Inc. (Nasdaq: AGRX) is a forward-thinking company specializing in women's healthcare. Their mission is to address the unmet health needs of today’s women by providing innovative contraceptive options. The company’s leading product, Twirla® (ethinyl estradiol and levonorgestrel transdermal system), is a once-weekly prescription contraceptive patch that offers an alternative to daily pills or longer-acting methods. Twirla employs Agile's proprietary Skinfusion® technology designed to improve patch adhesion and patient comfort.
Recently, Agile Therapeutics has reported significant financial and operational accomplishments. In the third quarter of 2023, Twirla achieved net revenue of $6.7 million, reflecting a 21% increase from the second quarter and a 122% increase year-over-year. The company projects positive cash flow from operations by the first quarter of 2024, backed by a strong gross margin that grew to 63% in the third quarter of 2023.
The company’s strategic focus includes expanding their market presence through partnerships and promotional efforts, notably targeting five key states with high reimbursement potential. Agile is also enhancing Twirla's availability through telemedicine platforms like Nurx, TwentyEight Health, and Pandia, aiming to broaden its reach further.
Operational expenses have been managed effectively, with a reported decrease in GAAP operating expenses to $8.2 million in the third quarter of 2023. This financial discipline, alongside the anticipated revenue, positions Agile Therapeutics favorably for sustainable growth.
Additionally, Agile Therapeutics has successfully completed the pay-off of their debt facility with Perceptive Advisors, leaving their balance sheet debt-free. Despite a delisting notice from Nasdaq, the company’s shares continue to trade on the OTC Market, maintaining its focus on executing its business plan and exploring strategic opportunities to maximize Twirla’s growth and shareholder value.
For more detailed updates, latest news, and information, you can visit their website at www.agiletherapeutics.com or follow them on Twitter @agilether.
Agile Therapeutics (Nasdaq: AGRX) has entered a securities purchase agreement for a sale of 2,425 Series A and Series B convertible preferred shares, along with Series A and B warrants, expected to raise approximately $4.85 million. Each preferred share is priced at $1,000 with a conversion price of $0.20. The Series A and B warrants allow purchases of up to 24,250,000 shares at an exercise price of $0.26. The company plans to utilize proceeds for working capital and will seek shareholder approval for a reverse stock split.
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced that CEO Al Altomari will participate in two investor conferences. The first is the Oppenheimer 32nd Annual Virtual Healthcare Conference on Thursday, March 17, 2022, at 2:00 p.m. ET, featuring a fireside chat. The second is the Maxim Group and M-Vest 2022 Virtual Growth Conference, with a live panel discussion titled Advances in Women’s Health, from Clinical to Commercial, scheduled for Monday, March 28, 2022, at 3:00 p.m. ET. More information is available on their website.
Agile Therapeutics (Nasdaq: AGRX) plans to release its fourth quarter and full year 2021 financial results on March 30, 2022, after the market closes. A live conference call will follow at 4:30 p.m. ET, during which the company will discuss its results and provide business updates. Interested investors can access the call via telephone or through a webcast available on the company's investor relations page. This announcement highlights Agile Therapeutics' commitment to transparency and investor engagement.
On January 10, 2022, the DOL, HHS, and Treasury issued guidance enhancing women's access to FDA-approved contraceptive products, reaffirming compliance with the Affordable Care Act. The HRSA updated Women's Preventative Services Guidelines, effective for plan years beginning 2023, mandating coverage of all FDA-approved contraceptives at no cost. Agile Therapeutics supports these guidelines, emphasizing the importance of personalized contraceptive access. The company’s product, Twirla®, a non-daily contraceptive patch, is designed to meet women's diverse needs.
Agile Therapeutics (Nasdaq: AGRX) announced a strategic alliance with Afaxys Pharma to promote Twirla®, a transdermal contraceptive system. This partnership aims to enhance access to Twirla for patients in the U.S. family planning community, benefiting over 31 million Americans who rely on community health centers. Afaxys, a leader in public health, will help ensure Twirla is affordable and widely available. Twirla is indicated for women with a BMI < 30 kg/m2 and is designed for weekly use as a non-invasive contraceptive option.
Agile Therapeutics, Inc. (Nasdaq: AGRX) announced that CEO Al Altomari will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13 at 7:30 a.m. ET. The presentation will be live-streamed and accessible via the investor relations section of Agile's website. Agile Therapeutics focuses on women's healthcare, offering non-daily contraceptive options, including their product Twirla, which utilizes proprietary transdermal patch technology. For further details, visit www.agiletherapeutics.com.
Agile Therapeutics, Inc. (Nasdaq: AGRX) announced that its Chairman and CEO, Al Altomari, will present at two upcoming conferences: the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022, and the Biotech Showcase from January 10-12, 2022.
The presentations will be available on-demand, with the H.C. Wainwright presentation starting at 7:00 a.m. ET on January 10, and the Biotech Showcase presentation at 11:00 a.m. ET on the same day. Details can be found in the investor relations section of Agile Therapeutics' website.
Agile Therapeutics (Nasdaq: AGRX) reported a strong third quarter for 2021, seeing a 61% increase in cycles of Twirla dispensed, totaling 9,747. Total prescriptions surged by 47% to 7,374, driven by new prescribers and refills, which rose by 86%. The company partnered with Pandia Health for telehealth access and secured Twirla's placement on California's Medi-Cal preferred drug list, benefiting 15 million beneficiaries. Despite a net loss of $16.8 million, Agile anticipates increased marketing spend to drive growth, with cash reserves reported at $14.7 million.
Agile Therapeutics (Nasdaq: AGRX), a women's healthcare company, is set to announce its third quarter 2021 financial results after market close on November 2, 2021. The live conference call will take place at 4:30 p.m. ET, and will be accessible via dial-in or webcast. Investors are encouraged to log in early to participate. Agile is known for its product Twirla, a non-daily contraceptive patch.
Agile Therapeutics, Inc. (Nasdaq: AGRX) has expressed strong support for Congressional Committee leaders advocating for the enforcement of the Affordable Care Act (ACA) concerning women's access to contraceptives. The company's CEO, Al Altomari, emphasized the importance of women having the right to make personal choices regarding contraception in consultation with healthcare providers. Agile Therapeutics recognizes the efforts of the Family Planning Coalition and its members in pushing for improved access to necessary birth control methods.
FAQ
What is the current stock price of AGILE THERAPEUTICS (AGRX)?
What is the market cap of AGILE THERAPEUTICS (AGRX)?
What is Agile Therapeutics' primary product?
How well did Agile Therapeutics perform financially in the third quarter of 2023?
What is Skinfusion® technology?
What are the company's future financial projections?
How is the company expanding its market presence?
What are the current trading circumstances of Agile Therapeutics' shares?
How did Agile Therapeutics manage their operational expenses?
What strategic initiatives is Agile Therapeutics currently pursuing?
What impact does the Biden-Harris Administration's new guidance have on Twirla?
Where can more information about Agile Therapeutics be found?
